The alumni have founded the medical technology startup Coherence Neuro that will work closely with Malliaras on this project. These new bioelectronic implants are designed to treat chronic diseases by combining flexible materials, AI-driven modelling, and cutting-edge microelectronics.
Project SPARCLE: A Pan-European Neurotech Initiative
The initiative, named Project SPARCLE (Small form factor implantable Pulse generAtoRs for Chronic and Lifestyle-related disease managEment), aims to create battery-less, implantable pulse generators for treating chronic conditions. These compact systems will support treatment of:
- Severe migraines
- Pancreatic cancer (adenocarcinoma)
- Spinal cord injuries
Innovating with Flexible Microelectrodes
Professor Malliaras’ Bioelectronics Laboratory at the University of Cambridge will lead the development of flexible microelectrodes using conductive polymers. These electrodes form the crucial interface with peripheral nerves, allowing for safe, effective stimulation without damaging sensitive tissues.
Advanced Electrode Materials for Precision
The use of advanced conductive polymer layers significantly reduces electrode impedance. This improves safety and signal performance, enabling reliable communication between implants and the nervous system.
Coherence Neuro: Alumni-Led Innovation
Joining the consortium is Coherence Neuro, a UK start-up founded by Professor Malliaras’ former PhD students Dr Ben Woodington and Dr Elise Jenkins. The company brings deep expertise in translating neurotechnology from lab to clinic.
Clinical Relevance and Future Applications
Coherence Neuro and other partners will lead real-world clinical use cases, ensuring that implant prototypes address actual healthcare needs. Applications span migraine management, spinal rehabilitation, and cancer-related neuromodulation.
A Vision for Future Healthcare
This collaborative project is a major step toward integrating bioelectronic implants into mainstream medical care. By miniaturizing devices and tailoring them for chronic disease, the consortium aims to enhance patient outcomes and reduce long-term healthcare costs.
